Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imgatuzumab + FOLFIRI in metastatic colorectal cancer
NCT01326000Phase 2Completed
- Sponsor
- Roche
- Start
- Apr 2011
- Primary completion
- Dec 2013
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 2 trial of imgatuzumab in metastatic colorectal cancer (mCRC), sponsored by Roche. Started Apr 2011; status: completed.
02
Drugs
imgatuzumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01326000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01326000.